Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 879Leukemia, Lymphocytic, Chronic, B-Cell 560Leukemia 426Hematologic Neoplasms 332Precursor Cell Lymphoblastic Leukemia-Lymphoma 331Myelodysplastic Syndromes 302Leukemia, Myelogenous, Chronic, BCR-ABL Positive 244Lymphoma, Non-Hodgkin 224Recurrence 222Lymphoma 196Neoplasms 195Multiple Myeloma 129Lymphoma, Mantle-Cell 119Lymphoma, Large B-Cell, Diffuse 114Lymphoma, Follicular 114Leukemia, Myelomonocytic, Chronic 89Lymphoma, B-Cell 88Lymphoma, B-Cell, Marginal Zone 85Leukemia, B-Cell 79Burkitt Lymphoma 64Leukemia, Myeloid, Chronic-Phase 57Waldenstrom Macroglobulinemia 56Leukemia, Myeloid 53Hodgkin Disease 47Hematologic Diseases 47Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 45Myeloproliferative Disorders 40Primary Myelofibrosis 39Bronchiolitis Obliterans Syndrome 35Anemia, Refractory, with Excess of Blasts 32

Interventions

gamma-Globulins 1Saline Solution 1Panzyga 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Agammaglobulinemia × Other hematologic neoplasm × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05645107 2026-04-13

EXCELL

Grifols Therapeutics LLC

Phase 3 Recruiting
386 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Bacterial Infections, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡